

Product datasheet for TR312959

FMO3 Human shRNA Plasmid Kit (Locus ID 2328)

Product data:

Product Type: shRNA Plasmids

Product Name: FMO3 Human shRNA Plasmid Kit (Locus ID 2328)

Locus ID: 2328

Synonyms: dJ127D3.1; FMOII; TMAU

pRS (TR20003) Vector:

E. coli Selection: Ampicillin Mammalian Cell Puromycin

Selection: Format:

Retroviral plasmids

FMO3 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = Components:

2328). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

NM 001002294, NM 001319173, NM 001319174, NM 006894, NM 006894.3, NM 006894.5, RefSeq:

NM 001002294.2, BC032016, BC032016.1, BM453951, NM 001002294.3

UniProt ID: P31513

Summary: Flavin-containing monooxygenases (FMO) are an important class of drug-metabolizing

> enzymes that catalyze the NADPH-dependent oxygenation of various nitrogen-, sulfur-, and phosphorous-containing xenobiotics such as therapeutic drugs, dietary compounds, pesticides, and other foreign compounds. The human FMO gene family is composed of 5 genes and multiple pseudogenes. FMO members have distinct developmental- and tissuespecific expression patterns. The expression of this FMO3 gene, the major FMO expressed in adult liver, can vary up to 20-fold between individuals. This inter-individual variation in FMO3 expression levels is likely to have significant effects on the rate at which xenobiotics are metabolised and, therefore, is of considerable interest to the pharmaceutical industry. This transmembrane protein localizes to the endoplasmic reticulum of many tissues. Alternative splicing of this gene results in multiple transcript variants encoding different isoforms. Mutations in this gene cause the disorder trimethylaminuria (TMAu) which is characterized by the accumulation and excretion of unmetabolized trimethylamine and a distinctive body

odor. In healthy individuals, trimethylamine is primarily converted to the non odorous


trimethylamine N-oxide.[provided by RefSeq, Jan 2016]



OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200

CN: techsupport@origene.cn

Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com





shRNA Design:

These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.

Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).